Update in Hematology and Medical Oncology: Evidence Published in 2011
Authors: Marc J. Kahn, Alice D. Ma, Lawrence N. Shulman
Journal: Annals of Internal Medicine (2012)

Updates21 August 2012Update in Hematology and Medical Oncology: Evidence Published in 2011Marc J. Kahn, MD, MBA, Alice D. Ma, MD, and Lawrence N. Shulman, MDMarc J. Kahn, MD, MBAFrom Tulane University School of Medicine, New Orleans, Louisiana; University of North Carolina School of Medicine, Chapel Hill, North Carolina; and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.Search for more papers by this author, Alice D. Ma, MDFrom Tulane University School of Medicine, New Orleans, Louisiana; University of North Carolina School of Medicine, Chapel Hill, North Carolina; and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.Search for more papers by this author, and Lawrence N. Shulman, MDFrom Tulane University School of Medicine, New Orleans, Louisiana; University of North Carolina School of Medicine, Chapel Hill, North Carolina; and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-156-7-201204030-00415 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This update reviews hematology and medical oncology articles published in 2011 that we consider important and relevant to practicing internists. These articles were chosen from those receiving a high ranking in ACP Journal Club PLUS. Important studies that appeared in the past year addressed the role of outpatient treatment for pulmonary embolism and showed that chemical thromboprophylaxis with low-molecular-weight heparin had no mortality benefit when given to hospitalized patients. In addition, the U.S. Food and Drug Administration approved several important oral anticoagulants that inhibit either factor Xa or thrombin. This past year also brought several exciting developments in malignant hematology. ...References1. Cleland JG, Coletta AP, Cullington D, Castiello T, de Boer RA, Clark AL. Clinical trials update from the European Society of Cardiology Meeting 2011: ARISTOTLE, SMART-AV: QLV substudy, SHIFT: echocardiography and quality of life substudies, European CRT Survey, and Basic Science Update. Eur J Heart Fail. 2011;13:1376-80. [PMID: 22102626] CrossrefMedlineGoogle Scholar2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. [PMID: 12637609] CrossrefMedlineGoogle Scholar3. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-9. [PMID: 19297565] CrossrefMedlineGoogle Scholar4. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8. [PMID: 19297566] CrossrefMedlineGoogle Scholar5. Brett AS, Ablin RJ. Prostate-cancer screening—what the U.S. Preventive Services Task Force left out. N Engl J Med. 2011;365:1949-51. [PMID: 22029759] CrossrefMedlineGoogle Scholar6. McNaughton-Collins MF, Barry MJ. One man at a time—resolving the PSA controversy. N Engl J Med. 2011;365:1951-3. [PMID: 22029758] CrossrefMedlineGoogle Scholar7. Volk RJ, Wolf AM. Grading the new US Preventive Services Task Force prostate cancer screening recommendation. JAMA. 2011;306:2715-6. [PMID: 22203540] CrossrefMedlineGoogle Scholar8. Chou R, LeFevre ML. Prostate cancer screening—the evidence, the recommendations, and the clinical implications. JAMA. 2011;306:2721-2. [PMID: 22203543] CrossrefMedlineGoogle Scholar9. Miller DC, Hollenbeck BK. Missing the mark on prostate-specific antigen screening. JAMA. 2011;306:2719-20. [PMID: 22203542] CrossrefMedlineGoogle Scholar10. Silvestri GA. Screening for lung cancer: it works, but does it really work? Ann Intern Med. 2011;155:537-9. [PMID: 21893614] LinkGoogle Scholar11. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366-73. [PMID: 21768458] CrossrefMedlineGoogle Scholar12. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23. [PMID: 20525992] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Tulane University School of Medicine, New Orleans, Louisiana; University of North Carolina School of Medicine, Chapel Hill, North Carolina; and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-0224.Corresponding Author: Marc J. Kahn, MD, MBA, Office of Admissions and Student Affairs, 131 South Robertson, Room 1555, Tulane University School of Medicine, New Orleans, LA 70131.Current Author Addresses: Dr. Kahn: Office of Admissions and Student Affairs, 131 South Robertson, Room 1555, Tulane University School of Medicine, New Orleans, LA 70131.Dr. Ma: University of North Carolina, Hemophilia and Thrombosis Center, 170 Manning Drive, Campus Box 7016, Chapel Hill, NC 27599.Dr. Schulman: Chief Medical Officer, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215.Author Contributions: Conception and design: M.J. Kahn, L.N. Shulman.Analysis and interpretation of the data: M.J. Kahn, L.N. Shulman.Drafting of the article: M.J. Kahn, A.D. Ma, L.N. Shulman.Critical revision of the article for important intellectual content: M.J. Kahn, L.N. Shulman.Final approval of the article: M.J. Kahn, L.N. Shulman.Administrative, technical, or logistic support: M.J. Kahn, L.N. Shulman.Collection and assembly of data: M.J. Kahn, L.N. Shulman.This article was published at www.annals.org on 19 April 2012. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 21 August 2012Volume 157, Issue 4Page: 276-283KeywordsApixabanAtrial fibrillationBreast cancerCancer screeningChronic myelocytic leukemiaComputed axial tomographyHemorrhageLung and intrathoracic tumorsMortalityStroke ePublished: 21 August 2012 Issue Published: 21 August 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...